NO301279B1 - Immobiliserte peptid-faststoffbærerpreparater, og fremgangsmåter for fremstilling av peptider - Google Patents

Immobiliserte peptid-faststoffbærerpreparater, og fremgangsmåter for fremstilling av peptider Download PDF

Info

Publication number: NO301279B1
Authority: NO; Norway
Prior art keywords: peptide; stated; group; preparation; solid carrier
Prior art date: 1989-02-17

Application number

NO913186A

Other languages

English (en)

Norwegian (no)

Other versions

NO913186L (no

NO913186D0 (no

Inventor

Hendrik Mario Geysen

Original Assignee

Coselco Mimotopes Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-02-17

Filing date

1991-08-15

Publication date

1997-10-06

1991-08-15 Application filed by Coselco Mimotopes Pty Ltd filed Critical Coselco Mimotopes Pty Ltd

1991-08-15 Publication of NO913186L publication Critical patent/NO913186L/no

1991-08-15 Publication of NO913186D0 publication Critical patent/NO913186D0/no

1997-10-06 Publication of NO301279B1 publication Critical patent/NO301279B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 132
238000000034 method Methods 0.000 title claims abstract description 36
239000007787 solid Substances 0.000 title claims description 33
238000002360 preparation method Methods 0.000 title claims description 28
102000004196 processed proteins & peptides Human genes 0.000 title description 35
150000001413 amino acids Chemical group 0.000 claims description 21
239000004472 Lysine Substances 0.000 claims description 13
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
150000001875 compounds Chemical class 0.000 claims description 12
150000002148 esters Chemical class 0.000 claims description 12
125000006239 protecting group Chemical group 0.000 claims description 12
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 10
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
-1 t-butyloxycarbonyl protecting group Chemical group 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 7
230000007704 transition Effects 0.000 claims description 7
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
230000002194 synthesizing effect Effects 0.000 claims description 6
125000003277 amino group Chemical group 0.000 claims description 5
239000004310 lactic acid Substances 0.000 claims description 5
235000014655 lactic acid Nutrition 0.000 claims description 5
WWYFPDXEIFBNKE-UHFFFAOYSA-N 4-(hydroxymethyl)benzoic acid Chemical compound OCC1=CC=C(C(O)=O)C=C1 WWYFPDXEIFBNKE-UHFFFAOYSA-N 0.000 claims description 4
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 4
125000000524 functional group Chemical group 0.000 claims description 4
JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims description 3
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical group NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 claims description 3
229940000635 beta-alanine Drugs 0.000 claims description 2
230000027455 binding Effects 0.000 abstract description 44
239000000203 mixture Substances 0.000 abstract description 16
230000009870 specific binding Effects 0.000 abstract description 12
238000000926 separation method Methods 0.000 abstract description 3
239000000243 solution Substances 0.000 description 52
238000003786 synthesis reaction Methods 0.000 description 25
230000015572 biosynthetic process Effects 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 19
238000012360 testing method Methods 0.000 description 19
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
230000007017 scission Effects 0.000 description 13
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
238000003776 cleavage reaction Methods 0.000 description 12
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 10
108090000565 Capsid Proteins Proteins 0.000 description 9
102100023321 Ceruloplasmin Human genes 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 9
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
238000010828 elution Methods 0.000 description 7
238000010647 peptide synthesis reaction Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
230000001588 bifunctional effect Effects 0.000 description 6
230000008859 change Effects 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000008878 coupling Effects 0.000 description 6
238000010168 coupling process Methods 0.000 description 6
238000005859 coupling reaction Methods 0.000 description 6
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 5
241001429318 Johnsongrass mosaic virus Species 0.000 description 5
241000710078 Potyvirus Species 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
241000700605 Viruses Species 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000012267 brine Substances 0.000 description 5
210000004899 c-terminal region Anatomy 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
229960000814 tetanus toxoid Drugs 0.000 description 5
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
238000010511 deprotection reaction Methods 0.000 description 4
238000011835 investigation Methods 0.000 description 4
238000006386 neutralization reaction Methods 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 4
229920000573 polyethylene Polymers 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000003756 stirring Methods 0.000 description 4
230000009897 systematic effect Effects 0.000 description 4
241001465754 Metazoa Species 0.000 description 3
230000006052 T cell proliferation Effects 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
MCRJIULNASZDCF-UHFFFAOYSA-N phenacyl 2-hydroxypropanoate Chemical compound CC(O)C(=O)OCC(=O)C1=CC=CC=C1 MCRJIULNASZDCF-UHFFFAOYSA-N 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
238000005406 washing Methods 0.000 description 3
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 2
101100131080 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) mpb70 gene Proteins 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
239000000556 agonist Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000008827 biological function Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000037029 cross reaction Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000003480 eluent Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
108010044655 lysylproline Proteins 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
NIQSFBXODLISCO-BQBZGAKWSA-N (2s)-1-[(2s)-2-aminopropanoyl]-n-methylpyrrolidine-2-carboxamide Chemical compound CNC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N NIQSFBXODLISCO-BQBZGAKWSA-N 0.000 description 1
UJAXSMBQBPJDHB-NSHDSACASA-N (2s)-2,6-diamino-2-[(2-methylpropan-2-yl)oxycarbonyl]hexanoic acid Chemical compound CC(C)(C)OC(=O)[C@@](N)(C(O)=O)CCCCN UJAXSMBQBPJDHB-NSHDSACASA-N 0.000 description 1
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
RQSHUOYCOORLTG-UHFFFAOYSA-N 9H-fluoren-9-ylmethyl 3-amino-2-hydroxypropanoate Chemical compound C1=CC=C2C(COC(=O)C(O)CN)C3=CC=CC=C3C2=C1 RQSHUOYCOORLTG-UHFFFAOYSA-N 0.000 description 1
101710146995 Acyl carrier protein Proteins 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
244000166102 Eucalyptus leucoxylon Species 0.000 description 1
235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241001467552 Mycobacterium bovis BCG Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000723811 Soybean mosaic virus Species 0.000 description 1
241001310178 Watermelon mosaic virus Species 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
229960004407 chorionic gonadotrophin Drugs 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000007822 coupling agent Chemical class 0.000 description 1
239000012043 crude product Substances 0.000 description 1
LABSLXOWZIMSBL-UHFFFAOYSA-N dehydrodiooniferyl alcohol Natural products O1C=2C(OC)=CC(C=CCOC)=CC=2C(CO)C1C1=CC=C(O)C=C1 LABSLXOWZIMSBL-UHFFFAOYSA-N 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000004992 fission Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
150000003956 methylamines Chemical class 0.000 description 1
KKHLKORVTUUSBC-YFKPBYRVSA-N n-(2,4-dinitrophenyl)-l-alanine Chemical compound OC(=O)[C@H](C)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O KKHLKORVTUUSBC-YFKPBYRVSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
229960003531 phenolsulfonphthalein Drugs 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
JTHRRMFZHSDGNJ-UHFFFAOYSA-N piperazine-2,3-dione Chemical group O=C1NCCNC1=O JTHRRMFZHSDGNJ-UHFFFAOYSA-N 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000003385 ring cleavage reaction Methods 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
RVZPDKXEHIRFPM-UHFFFAOYSA-N tert-butyl n-(6-aminohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCN RVZPDKXEHIRFPM-UHFFFAOYSA-N 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/824—Immunological separation techniques
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO913186A 1989-02-17 1991-08-15 Immobiliserte peptid-faststoffbærerpreparater, og fremgangsmåter for fremstilling av peptider NO301279B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AUPJ278889		1989-02-17
PCT/AU1990/000062 WO1990009395A1 (en)	1989-02-17	1990-02-16	Method for the use and synthesis of peptides

Publications (3)

Publication Number	Publication Date
NO913186L NO913186L (no)	1991-08-15
NO913186D0 NO913186D0 (no)	1991-08-15
NO301279B1 true NO301279B1 (no)	1997-10-06

Family

ID=3773722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO913186A NO301279B1 (no)	1989-02-17	1991-08-15	Immobiliserte peptid-faststoffbærerpreparater, og fremgangsmåter for fremstilling av peptider

Country Status (12)

Country	Link
US (2)	US5539084A (de)
EP (2)	EP0628570A1 (de)
JP (1)	JPH04504416A (de)
AT (1)	ATE123780T1 (de)
AU (1)	AU642403B2 (de)
CA (1)	CA2047191A1 (de)
DE (1)	DE69020143T2 (de)
DK (1)	DK0458841T3 (de)
ES (1)	ES2075196T3 (de)
NO (1)	NO301279B1 (de)
NZ (1)	NZ232562A (de)
WO (1)	WO1990009395A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5866363A (en)	1985-08-28	1999-02-02	Pieczenik; George	Method and means for sorting and identifying biological information
US5744101A (en)	1989-06-07	1998-04-28	Affymax Technologies N.V.	Photolabile nucleoside protecting groups
US5959087A (en) *	1989-08-07	1999-09-28	Peptide Technology, Ltd.	Tumour necrosis factor binding ligands
JP3443119B2 (ja)	1989-08-07	2003-09-02	ペプテックリミテッド	腫瘍壊死因子結合リガンド
US20030225254A1 (en) *	1989-08-07	2003-12-04	Rathjen Deborah Ann	Tumour necrosis factor binding ligands
DE3935572A1 (de) *	1989-10-25	1991-05-02	Biotechnolog Forschung Gmbh	Verfahren zur peptidsynthese und traeger dafuer
WO1992010588A1 (en)	1990-12-06	1992-06-25	Affymax Technologies N.V.	Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
US20010021513A1 (en) *	1991-11-21	2001-09-13	Puijk Wouter Cornelis	Test device comprising a plate containing a multiplicity of wells with an associated metering device, as well as a kit which comprises these devices and use of the devices
EP0545198B1 (de) *	1991-11-29	1999-09-15	Hoechst Aktiengesellschaft	Peptide mit insulinartiger Wirkung
AU4580093A (en) *	1992-07-22	1994-02-14	Proteus Molecular Design Limited	Polypeptide antigens of mycobacterium bovis
US5702672A (en) *	1992-10-08	1997-12-30	Warner-Lambert Company	Apparatus and method for multiple simultaneous synthesis
US5324483B1 (en) *	1992-10-08	1996-09-24	Warner Lambert Co	Apparatus for multiple simultaneous synthesis
US5567391A (en) *	1992-10-08	1996-10-22	Warner-Lambert Company	Apparatus for multiple simultaneous synthesis
US5714127A (en) *	1992-10-08	1998-02-03	Warner-Lambert Company	System for multiple simultaneous synthesis
NZ257077A (en) *	1992-11-06	1997-05-26	Chiron Mimotopes Pty Ltd	Support for synthesis of modular polymers
PT1156059E (pt) *	1993-06-21	2007-10-19	Aventis Pharma Inc	Ligantes cliváveis selectivamente com base num grupo de metionina e um grupo éster
US5380668A (en) *	1993-07-06	1995-01-10	University Of Utah Research Foundation	Compounds having the antigenicity of hCG
WO1996020947A1 (en) *	1994-12-30	1996-07-11	Chiron Corporation	Method for the controlled synthesis of polynucleotide mixtures which encode desired mixtures of peptides
US5958792A (en) *	1995-06-07	1999-09-28	Chiron Corporation	Combinatorial libraries of substrate-bound cyclic organic compounds
WO1997012897A1 (en) *	1995-10-03	1997-04-10	The Penn State Research Foundation	Method to identify a surface-bound molecule
US7517952B1 (en) *	1997-02-25	2009-04-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) *	1997-02-25	2003-10-02	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
US20060269532A1 (en) *	1997-02-25	2006-11-30	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) *	1997-02-25	2006-02-02	Corixa Corporation	Prostate-specific polypeptides and fusion polypeptides thereof
US6143909A (en) *	1997-02-26	2000-11-07	Eli Lilly And Company	Selective epoxidation process for preparing pharmaceutical compounds
US7335351B2 (en) *	1997-03-19	2008-02-26	The University Of Arkansas For Medical Sciences	Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US7282198B2 (en) *	1997-03-19	2007-10-16	The University Of Arkansas For Medical Sciences	Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US6294344B1 (en) *	1997-03-19	2001-09-25	The Board Of Trustees Of The University Of Arkansas	Methods for the early diagnosis of ovarian cancer
US7084239B1 (en) *	1997-10-08	2006-08-01	The United States Of America As Represented By The Department Of Health And Human Services	Cancer peptides of NY-ESO-1/CAG-3
US20020061848A1 (en) *	2000-07-20	2002-05-23	Ajay Bhatia	Compounds and methods for treatment and diagnosis of chlamydial infection
US9289487B2 (en) *	1999-09-14	2016-03-22	Antigen Express, Inc.	II-key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) *	1999-09-14	2002-08-13	Antigen Express, Inc.	Hybrid peptides modulate the immune response
US20030235594A1 (en) *	1999-09-14	2003-12-25	Antigen Express, Inc.	Ii-Key/antigenic epitope hybrid peptide vaccines
US6919187B2 (en) *	2000-04-21	2005-07-19	Corixa Corporation	Compounds and methods for treatment and diagnosis of chlamydial infection
US6656700B2 (en) *	2000-05-26	2003-12-02	Amersham Plc	Isoforms of human pregnancy-associated protein-E
WO2002006384A1 (en) *	2000-07-14	2002-01-24	Mimotopes Pty Ltd	Activated modular grafted polymeric surfaces
JP4503801B2 (ja) *	2000-09-08	2010-07-14	独立行政法人科学技術振興機構	新規ヒト癌・精巣抗原及びその遺伝子
US20020123474A1 (en) *	2000-10-04	2002-09-05	Shannon Mark E.	Human GTP-Rho binding protein2
EP1404841B1 (de) *	2000-10-31	2011-08-17	Eisai Inc.	Nucleinsäure kodierend für cyp1b1 und methoden zur verwendung
JP2005505242A (ja) *	2001-03-07	2005-02-24	マンカインドコーポレイション	癌用抗新生血管系調製物
US20040078837A1 (en) *	2001-08-02	2004-04-22	Shannon Mark E.	Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12
US20050239043A1 (en) *	2002-02-26	2005-10-27	Harding Fiona A	Subtilisin carlsberg proteins with reduced immunogenicity
AU2003243151A1 (en) *	2002-08-16	2004-03-03	Agensys, Inc.	Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2499123A1 (en)	2002-09-17	2004-04-15	Antigen Express, Inc.	Ii-key/antigenic epitope hybrid peptide vaccines
US7179645B2 (en) *	2002-09-24	2007-02-20	Antigen Express, Inc.	Ii-Key/antigenic epitope hybrid peptide vaccines
US6910785B2 (en) *	2003-01-22	2005-06-28	Cooper Technologies Company	Industrial luminaire with prismatic refractor
US20040185499A1 (en) *	2003-03-20	2004-09-23	Jolley Michael E.	Method of epitope scanning using fluorescence polarization
US20050095648A1 (en) *	2003-10-30	2005-05-05	Mario Geysen	Method for designing linear epitopes and algorithm therefor and polypeptide epitopes
RU2526196C2 (ru) *	2005-07-27	2014-08-20	Онкотерапи Сайенс, Инк.	Связанный с раком толстого кишечника ген том34
CA2628241C (en)	2005-11-07	2016-02-02	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
CN101578102B (zh) *	2007-01-05	2013-07-17	印第安纳大学研究及科技有限公司	在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
MX2009008241A (es)	2007-02-15	2009-10-08	Univ Indiana Res & Tech Corp	Co-agonistas de receptor de glucagon/glp-1.
EP2044949A1 (de)	2007-10-05	2009-04-08	Immutep	Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
JP5771005B2 (ja) *	2007-10-30	2015-08-26	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
CA2707861A1 (en)	2007-10-30	2009-05-07	Indiana University Research And Technology Corporation	Glucagon antagonists
WO2009099763A1 (en) *	2008-01-30	2009-08-13	Indiana University Research And Technology Corporation	Ester-based peptide prodrugs
TWI541023B (zh) *	2008-06-17	2016-07-11	印第安納大學科技研究公司	在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
EP2300037B1 (de)	2008-06-17	2016-03-30	Indiana University Research and Technology Corporation	Coagonisten des glucagon/glp-1 rezeptors
TWI474835B (zh) *	2008-06-17	2015-03-01	Univ Indiana Res & Tech Corp	用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
RU2550696C2 (ru)	2008-12-19	2015-05-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Основанные на амидах пролекарства пептидов глюкагонового надсемейства
CA2750922A1 (en) *	2009-01-28	2010-08-05	Antigen Express, Inc.	Li-key hybrid peptides that modulate the immune response to influenza
WO2010148089A1 (en)	2009-06-16	2010-12-23	Indiana University Research And Technology Corporation	Gip receptor-active glucagon compounds
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
EP2528618A4 (de)	2010-01-27	2015-05-27	Univ Indiana Res & Tech Corp	Glucagon-antagonisten- und gip-agonisten-konjugate sowie zusammensetzungen zur behandlung von stoffwechselerkrankungen und adipositas
CA2797095A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
WO2011143208A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
MX2012014576A (es)	2010-06-24	2013-02-21	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida.
SG190066A1 (en)	2010-10-29	2013-06-28	Lonza Ag	Diketopiperazine forming dipeptidyl linker
WO2012073459A1 (en)	2010-12-02	2012-06-07	Oncotherapy Science, Inc.	Tomm34 peptides and vaccines including the same
WO2012088116A2 (en)	2010-12-22	2012-06-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting gip receptor activity
CN103857408B (zh)	2011-06-22	2017-04-12	印第安那大学科技研究公司	胰高血糖素/glp‑1受体协同激动剂
MX2013015168A (es)	2011-06-22	2014-03-31	Univ Indiana Res & Tech Corp	Co-agonista del receptor de glucagon/glp-1.
HK1198810A1 (en)	2011-11-17	2015-06-12	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
EP2639299A1 (de) *	2012-03-16	2013-09-18	Invectys	Aus Telomerase abgeleitete, universelle Krebspeptide
US9340600B2 (en)	2012-06-21	2016-05-17	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
JP6538645B2 (ja)	2013-03-14	2019-07-03	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン‐インクレチン複合物
WO2014154904A1 (en)	2013-03-28	2014-10-02	Invectys	A cancer vaccine for cats
WO2014154905A1 (en)	2013-03-28	2014-10-02	Invectys	A cancer vaccine for dogs
DK3063280T3 (da)	2013-10-28	2019-11-11	Invectys	Genelektrooverførsel ind i hudceller
US10183065B2 (en)	2013-10-28	2019-01-22	Invectys	Telomerase encoding DNA vaccine
GB201322626D0 (en)	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
US9682123B2 (en)	2013-12-20	2017-06-20	The Trustees Of Columbia University In The City Of New York	Methods of treating metabolic disease
US10232020B2 (en)	2014-09-24	2019-03-19	Indiana University Research And Technology Corporation	Incretin-insulin conjugates
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
WO2017027858A1 (en)	2015-08-12	2017-02-16	The Trustees Of Columbia University In The City Of New York	Methods of treating volume depletion and kidney injury
WO2018206512A1 (en)	2017-05-09	2018-11-15	Invectys	Recombinant measles vaccine expressing htert
KR20240133644A (ko) *	2023-02-27	2024-09-04	에스피투티엑스주식회사	응집 방지 기능을 갖는 생물학적 고분자 합성용 기재 및 이를 이용한 생물학적 고분자 합성 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3983001A (en) *	1972-05-10	1976-09-28	Ceskoslovenska Akademie Ved	Isolation of biologically active compounds by affinity chromatography
US3988307A (en) *	1974-09-06	1976-10-26	The United States Of America As Represented By The Secretary Of The Department Of Health, Education And Welfare	Solid phase synthesis of peptides with carboxyl-terminal amides
US5217869A (en) *	1987-10-13	1993-06-08	Terrapin Technologies, Inc.	Method to produce immunodiagnostic reagents
US5133866A (en) *	1988-03-24	1992-07-28	Terrapin Technologies, Inc.	Method to identify analyte-bending ligands
US4963263A (en) *	1988-03-24	1990-10-16	Terrapin Technologies, Inc.	Method of identity analyte-binding peptides
US5340474A (en) *	1988-03-24	1994-08-23	Terrapin Technologies, Inc.	Panels of analyte-binding ligands
US5409611A (en) *	1988-03-24	1995-04-25	Terrapin Technoogies, Inc.	Method to identify analyte-binding ligands

1990
- 1990-02-16 DE DE69020143T patent/DE69020143T2/de not_active Expired - Fee Related
- 1990-02-16 WO PCT/AU1990/000062 patent/WO1990009395A1/en not_active Ceased
- 1990-02-16 ES ES90903300T patent/ES2075196T3/es not_active Expired - Lifetime
- 1990-02-16 NZ NZ232562A patent/NZ232562A/xx unknown
- 1990-02-16 EP EP94201174A patent/EP0628570A1/de not_active Withdrawn
- 1990-02-16 AT AT90903300T patent/ATE123780T1/de active
- 1990-02-16 CA CA002047191A patent/CA2047191A1/en not_active Abandoned
- 1990-02-16 US US07/752,437 patent/US5539084A/en not_active Expired - Lifetime
- 1990-02-16 EP EP90903300A patent/EP0458841B1/de not_active Expired - Lifetime
- 1990-02-16 JP JP2503570A patent/JPH04504416A/ja active Pending
- 1990-02-16 AU AU49869/90A patent/AU642403B2/en not_active Ceased
- 1990-02-16 DK DK90903300.3T patent/DK0458841T3/da not_active Application Discontinuation
1991
- 1991-08-15 NO NO913186A patent/NO301279B1/no unknown
1995
- 1995-06-07 US US08/475,213 patent/US5783674A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO913186L (no)	1991-08-15
DE69020143D1 (de)	1995-07-20
EP0458841A1 (de)	1991-12-04
EP0458841A4 (en)	1992-08-26
AU642403B2 (en)	1993-10-21
NO913186D0 (no)	1991-08-15
US5783674A (en)	1998-07-21
EP0458841B1 (de)	1995-06-14
US5539084A (en)	1996-07-23
DE69020143T2 (de)	1996-01-25
NZ232562A (en)	1992-10-28
AU4986990A (en)	1990-08-23
ATE123780T1 (de)	1995-06-15
EP0628570A1 (de)	1994-12-14
JPH04504416A (ja)	1992-08-06
DK0458841T3 (da)	1995-11-20
ES2075196T3 (es)	1995-10-01
WO1990009395A1 (en)	1990-08-23
CA2047191A1 (en)	1990-08-18

Publication	Publication Date	Title
US5783674A (en)	1998-07-21	Method for the use and synthesis of peptides
Maeji et al.	1990	Multi-pin peptide synthesis strategy for T cell determinant analysis
AU683184B2 (en)	1997-10-30	Libraries of modified peptides with protease resistance, derivatives thereof and methods of producing and screening such
CA2424611C (en)	2011-01-25	Identification of protein binding sites
CA1106360A (en)	1981-08-04	Antigenically active polypeptide and a process for its preparation
US5811387A (en)	1998-09-22	Peptoid mixtures
JPH04501709A (ja)	1992-03-26	ペプチド合成法および該法における固体支持体の使用
CN1038034C (zh)	1998-04-15	肽模拟物的快速合成和筛选
US5258454A (en)	1993-11-02	Peptide synthesis method and solid support for use in the method
US5191015A (en)	1993-03-02	Polymers and polymer-peptide conjugates
JPH10511078A (ja)	1998-10-27	免疫刺激剤
NO149998B (no)	1984-04-24	Analogifremgangsmaate til fremstilling av peptider med ubiquitinlignende aktivitet
NO844123L (no)	1985-04-18	Fremgangsmaate for fremstilling av nonapeptider og dodekopeptider
FR2717081A1 (fr)	1995-09-15	Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
WO1991019984A1 (en)	1991-12-26	Carboxyl-terminal protein sequencing method and apparatus
US4327075A (en)	1982-04-27	Synthetic antigenically-active polypeptide and a process for its preparation
GB2282813A (en)	1995-04-19	Annular antigen scaffolds comprising thioether linkages
Selvam et al.	2015	Synthesis of biologically active hydrophobic peptide by using novel polymer support: improved Fmoc solid phase methodology
JP4258271B2 (ja)	2009-04-30	ポリアミノ酸担体
US5932692A (en)	1999-08-03	Antigenic peptides
JP4568842B2 (ja)	2010-10-27	熱帯熱マラリア原虫のエノラーゼ蛋白質の部分ペプチドの製造方法
Maeji et al.	1992	Simultaneous multiple synthesis of peptide-carrier conjugates
JP2001226371A (ja)	2001-08-21	ダイオキシン誘導体およびこれを使用した測定法
Love	1991	Studies towards the chemical synthesis of the 18 kDa antigenic protein from Mycobacterium leprae: a thesis presented in partial fulfilment of the requirements for the degree of Ph. D. in Chemistry at Massey University
EP4662235A1 (de)	2025-12-17	Verfahren zur chemischen synthese von einzelkettenantikörperfragmenten und dadurch erhaltene produkte